Source comparison
TB-500 Safe Long Term Use: Comparison Analysis
2–4 weeks Strong (animal + limited human) Accelerated wound healing, angiogenesis, reduced inflammation Minimal. Injection site reactions in <5% Baseline inflammatory markers Supported by evidence for acute tissue repair 4–6 weeks Moderate (animal models) Cont
This comparison does not assign a generated winner or score.
- 2–4 weeks
- Strong (animal + limited human)
- Accelerated wound healing, angiogenesis, reduced inflammation
- Minimal. Injection site reactions in <5%
- Baseline inflammatory markers
- Supported by evidence for acute tissue repair
- 4–6 weeks
- Moderate (animal models)
- Continued tissue remodeling, collagen deposition
- Low. No documented serious AEs in published trials
- Pre/post inflammatory panel, subjective symptom tracking
- Maximum supported duration for single-cycle use
- 6–8 weeks
- Weak (extrapolation from animal data)
- Diminishing returns. Repair benefits plateau
- Moderate. Unknown antibody formation risk, receptor desensitization possible
- Anti-Tβ4 antibody titer measurement (research setting only)
- Approaching evidence ceiling. Washout recommended
- 8–12 weeks continuous
- None (no human data)
- Unclear. No additional repair benefit demonstrated
- Unknown. Immune sensitization, chronic inflammatory modulation unstudied
- Comprehensive immune panel, organ function testing
- Not supported by current evidence base
- 12+ weeks continuous
- None
- Speculative at best
- High unknown risk. Zero long-term human safety data
- N/A. Exceeds all published protocols
- Outside regulatory and evidence-based practice